Introduction
Ventricular tachycardias are a diverse group of arrhythmias with widely differing properties and outcomes. This article will concentrate on those due to structural and, in particular, ischaemic heart disease as they are by far the commonest and most dangerous.
Diagnosis of ventricular tachycardia
Thirty per cent of all patients with ventricular tachycardia (VT) die within 12 months of diagnosis. In those with severe structural heart disease the mortality in the first year is around 80%.' Appropriate treatment considerably reduces mortality and can only be given if the condition is correctly diagnosed.
In current medical practice there can be few commonly occurring conditions which are surrounded by so much misunderstanding and preconception. Recent studies show that there is approximately a 40% error rate in diagnosing broad complex tachycardia2 whereas correct analysis ofthe electrocardiogram (ECG) features alone should allow the diagnosis of VT to be made correctly in over 90% of cases. 3 The errors are in part due to a poor understanding of the electrocardiographic criteria for distinguishing VT from supraventricular tachycardia (SVT), particularly as far as the reliability of individual indicators is concerned.
All grades of hospital doctor confuse VT with SVT. Usually the mistake is to diagnose SVT when the rhythm is in fact VT. 3 The possible reasons and motives for this bias are fascinating. It is almost as if doctors feel more comfortable with SVT and that they are so unwilling to get involved in the complexities of the management of VT, that they 'prefer' to make the diagnosis of SVT rather than VT. Misdiagnosis may be a consequence ofcommon misconceptions including the idea that VT always causes severe haemodynamic disturbance. In fact patients often present with minor symptoms such as palpitations.4 It may be a failure to recognize that VT is more common than SVT as a cause of broad complex tachycardia5 and that broad complex tachycardia in patients with ischaemic heart disease is almost invariably VT.6 There is still a misconception that verapamil is safe, whereas the studies suggest that it causes circulatory collapse in such a high proportion of patients7 that it could be regarded as negligent to use it in patients with broad complex tachycardias, unless the diagnosis of SVT were to be firmly established. There may be a feeling that the subtleties of electrocardiographic interpretation are the province of electrophysiologists and that the simple practising clinician might as well toss a coin as spend time comparing ECGs. This complete lack of self-confidence is typified by the ready acceptance of previously made diagnoses ('known SVT'). 8 From the practical point of view there are two phases to the diagnosis of ventricular tachycardia. The first is the initial presentation. The patient may either be extremely ill or virtually asymptomatic but the only information available is from the history, clinical findings and the ECG during tachycardia. Here, sometimes decisions have to be made rapidly with less than full information and it may not be possible to diagnose the origin of the arrhythmia accurately. Then it may be sufficient to call the arrhythmia 'broad complex tachycardia' provided that the potential mechanisms are understood and that the treatment given is appropriate to all the potential causes. Following the restoration of sinus rhythm, there is much more electrocardiographic information and the process of planning long-term management begins. In this second phase, the label broad complex tachycardia is unacceptable as it gives no idea ofprognosis and no grounds on which to choose therapeutic agents.
Because all forms of ventricular tachycardia (with the exception of the rare fascicular tachycardia) produce complexes of 120 ms or more, it is usually the presence of broad complexes that first raises the possibility of ventricular tachycardia. Apart from VT the possible alternative causes of broad complex tachycardia are: (1) IfVT is recurring frequently, provocation testing may not be necessary to demonstrate whether a drug is effective, but in the more usual situation, the frequency of spontaneous VT is such that some form of provocation is necessary if only to reduce the time required to be confident that the treatment is protective.33 Drug therapy guided by noninvasive testing can undoubtedly be effective if the protocol is carefully designed and strictly adhered to34 but there are no reliable studies comparing this approach to the more invasive stimulation techniques. The ESVEM trial (electrophysiologic study versus electrocardiographic monitoring35) which is due to be completed in 1991 should answer some of the questions but it seems likely that both methods will be shown to have their place36 and until EPS is more widely available in the UK the comparison may be largely academic: many hospitals will have to rely on Holter-guided therapy for lack of electrophysiological facilities.
EPS is not wholly reliable and even in controlled laboratory conditions its reproducibility is imperfect.37'38 Drugs that are found to be effective with provocation testing are not always effective longterm39 when the underlying disease process may well have progressed.' Provocation by exercise testing is probably almost as reproducible and more physiological,4' but only in those 20% of patients whose arrhythmia is reproducibly induced by exercise before the introduction of drug. 42 Despite the apparent limitations ofprogrammed stimulation numerous studies have demonstrated a number of facts. One is that patients with inducible sustained VT are at higher risk than those in whom VT is not inducible.434' Another is that in those patients with inducible sustained VT a drug which suppresses it in the electrophysiology laboratory will reduce the subsequent risk of sudden death provided it does not also have proarrhythmic effect at the time of study.' Also failure to find a drug that will suppress inducible VT is associated with a significantly higher mortality."45 Up to 50% of patients may remain inducible after a number of drug trials and these patient are at high risk. 46 This suggests either that drug testing does identify successful drugs or that the process of drug testing identifies a group of patients with a better prognosis (regardless of the treatment).47 It is likely that the drugs are responsible for the improvement in prognosis as there is a high reported incidence of arrhythmic events among patients who initially respond to a drug but later default from treatment. ' In general the more aggressive the attempts to provoke VT the more likely it is to be provoked, but with very unphysiological stimulation protocols, the VT so initiated may not be the same as the spontaneously occurring VT (as judged by comparison of the surface ECGs). Attempts to prevent the initiation of an 'unnatural VT' may not predict the correct treatment of the spontaneously occurring VT.
Potential risks of drug treatment

Proarrhythmia
In patients with ischaemic heart disease the setting for VT is thought to be the juxtaposition of islands of ischaemic or fibrous tissue and the surrounding normal myocardial cells. Under these conditions conduction in the damaged area may be sufficiently slowed that the refractory period of the surrounding normal areas has been completed by the time the wave of excitation has spread through the damaged area. This then creates a perpetual circuit due to re-entry. Drugs may modify the circuit by increasing the refractory period of normal tissue, but many antiarrhythmic agents also slow conduction and thereby may facilitate other circuits which can be as dangerous or more dangerous than the circuit which has been abolished. Usually, because they are other circuits, they will be represented by surface ECG morphologies that are distinct from those of the original tachycardia and they can therefore be recognized as being due to a proarrhythmic effect.
The phenomenon of proarrhythmia encompasses the expression of other circuits as described above and also the worsening of spontaneous arrhythmias (for example, a ventricular tachycardia which has previously been non-sustained may become sustained) under the influence of an antiarrhythmic drug. Although it has long been recognized as a potential problem particularly of Class I agents, it has only recently, with the publication ofthe CAST study,48 been appreciated that it is sufficiently common seriously to influence the risk-benefit ratio even to the extent of causing overall harm, particularly in a population with a relatively low risk before treatment. Even in high risk groups empirical drug treatment may reduce survival. 49 It is quite clear now that some drugs or groups of drugs are more likely to produce proarrhythmic effects than others. from the patients with long-standing ischaemic heart disease or dilated cardiomyopathy) demonstrated at least as good survival in patients treated with amiodarone empirically as in those whose drug treatment was designed on an individual basis.5' Major difficulties arise in demonstrating (or even defining) proarrhythmia in a way that allows scientific analysis. Exactly as with untreated arrhythmias, proarrhythmic effects may be demonstrated when they arise spontaneously or following some form of deliberate provocation. Eighty per cent of spontaneously occurring proarrhythmic events occur within 6 days of starting a new drug.52
When patients develop VT while on medication there may sometimes be difficulty in deciding whether the VT represents a proarrhythmic effect or the breakthrough of the old arrhythmia. However, whatever the mechanism, the observation of an important spontaneous arrhythmia occurring whilst on treatment will at least cast some doubt on the wisdom of using that particular drug.
Greater difficulties arise when proarrhythmic effects can only be demonstrated by provocation. Non-invasive provocation, of which exercise testing is the commonest form, demonstrates only about half as many episodes of proarrhythmia as more aggressive invasive electrophysiological studies. Yet it is far from clear what is the prognostic implication of proarrhythmia as revealed by EPS or exercise testing. Exercise testing has the major theoretical advantage that it is both physiological and natural, but if exercise (or any resultant myocardial ischaemia) does not happen to be an important trigger for the iatrogenic arrhythmia then clearly a negative exercise test result should not provide much reassurance.
Just as the incidence and risk of spontaneous VT increases with the severity of structural heart disease, so does the incidence and risk of proarr-
and diuretics as well.5354 It is these patients with badly damaged hearts that particularly need the most thorough individual assessment of the riskbenefit ratio, and this implies invasive provocation studies.
Which drugs?
There is no universally accepted protocol for the drug treatment of VT but some basic concepts are valuable. (1) All antiarrhythmic drugs are potentially proarrhythmic, although ,3-blockers are probably the least culpable in this respect.50'55'56 (2) All antiarrhythmic drugs with the exception of amiodarone in conventional doses are negatively inotropic, and P-blockers are the worst (3) pblockers either with class III activity (sotalol57'58) or without (propranolol59) are being increasingly used in the treatment of VT, although their role may be greatest in catecholamine-sensitive VT' (e.g. exercise induced or induced by isoprenaline) rather than in the commonest forms of VT following myocardial infarction.6' Combination therapy with class I drugs is an exciting area of investigation62 as there is a suggestion that 13-blockers may control the proarrhythmic effects ofclass I agents.63 (4) The only drugs that have shown an improvement in survival when used empirically are ,BblockersM and amiodarone,51 and they have only shown a beneficial effect in the first year after myocardial infarction.
Non-drug management
Patients at high risk who do not respond to drugs during arrhythmia suppression trials form an obvious group where alternative management needs to be considered. Similarly those who demonstrate proarrhythmic effects with more than one drug may be as much at risk as the non-responder. There are now two alternative approaches. Firstly, there are direct approaches to modify the structure of the arrhythmic circuit. Secondly, the implantable cardioverter defibrillator will electrically pace or cardiovert sustained VT or ventricular fibrillation to sinus rhythm. after the procedure whereas previously drugs were ineffective. Five-year survival after surgery is around 60%, the main cause of death being heart failure. The resuts of transvenous ablation for VT are at present very poor and in marked contrast to the results ofablation for supraventricular arrhythmias67 which probably reflects the complexity ofthe substrates responsible for ischaemic VT.
A surprisingly high mortality of 7% has been reported for transvenous catheter ablation of VT.68 This is much higher than that due to other ablation procedures67 and probably reflects the seriousness of the underlying disease as well as the problems of high energy shocks in the left ventricle.
Surgical ablation/endocardial resection has a relatively high operative mortality of around 15%, as many patients have very poor left ventricular function and can ill afford the loss of any functioning myocardium. Patients at particularly high risk are those with poor left ventricular function, polymorphic VT, diffuse myocardial damage ('ischaemic cardiomyopathy' rather than a resectable scar or aneurysm) and previous cardiac surgery. 7' (b) The implantable cardioverter defibrillator This device is capable of recognizing VT or ventricular fibrillation and converting it to sinus rhythm. Rapid changes in technology have already ironed out some of the problems with the early devices and current models are capable of delivering 100-150 shocks with relatively little distur-bance to the patient. Further improvements now being evaluated include a completely transvenous system and the incorporation of antitachycardia pacing facilities which will enable many arrhythmias to be terminated without the need for high energy discharges and thereby increasing the longevity of the units. The implantable cardioverter defibrillator (ICD) can be used in conjunction with any ofthe treatment modalities already discussed. 72 The ICD has proved highly successful in the management of VT, with an incidence of sudden death after implantation as low as 2% in the first year and 7% at 4 years.73 It can be used in patients for whom no other method is practicable or in those for whom other methods have been unsuccessful.
The risks of death due to implantation using a thoracotomy are surprisingly high in some series (up to 4%) but this may be reduced by transvenous systems. Many other complications similar to but more frequent than those experienced in standard pacemaker implantation (infection, lead displacement, device malfunction, etc.) have all been reported. Inappropriate discharge of the devices have occurred in 40-50% of all patients. Such problems are likely to improve rapidly with advances in technology.
Current ICD systems cost about £12,000 to £15,000 and the UK Department of Health has yet to agree appropriate funding for them which places unnecessary and unfair strains on the patients and the staff caring for them.
Conclusions
Drug treatment remains the first goal for the management of sustained VT, but it has become very important to examine critically the evidence that a particular regimen is effective and that it does not produce new arrhythmias. Where VT is recurring frequently it may be sufficient to rely on non-invasive methods of assessing response to treatment, but in most instances the quickest way to arrive at the conclusion that a drug regimen is effective and without proarrhythmic effects is by EPS. Simple VT stimulation equipment is not expensive and any cardiologist trained in invasive techniques should be able to master a suitable protocol even in a district general hospital. Indeed until VT stimulation is more widely practised patients will continue to be treated empirically because of the limited number of specialist centres able to carry out antiarrhythmic drug testing.
Patients at high risk are those with significant myocardial damage. If a suitable drug or simple drug combination cannot be found then the choice lies between an ICD and ablation/resection. Factors favouring surgery would be: (1) frequent VT which would rapidly deplete an ICD; (2) easily inducible VT with one or two morphologies at most; (3) associated reversible ischaemia for which surgery was contemplated; (4) ventricular aneursym (particularly anterior); and (5) patient preference. ICD patch electrodes can be inserted at the time of surgery to facilitate the subsequent implantation of an ICD if it becomes necessary.
Factors favouring an ICD would be: (1) infrequent episodes; (2) very poor left ventricular function; (3) partial success with drug therapy; (4) multiple morphologies of VT; (5) no other cardiac surgery required; and (6) patient preference.
Recommendations for non-sustained VT are very much more difficult to make because prediction of risk is less precise. The most difficult decision is whether to treat at all, and this has to be based on the clinical presentation (syncope, cardiac arrest, palpitations or chance finding) and the degree of underlying heart disease (ejection fraction or equivalent). Of the various treatment modalities, the ICD is the least appropriate and ablative methods may be frustrated by difficulties in mapping. For these reasons drugs are the commonest method of treatment.
